Future research should focus on the development of targeted therapies targeting RAD51, with the goal of enhancing chemotherapy sensitivity by down-regulating RAD51 expression, ultimately improving survival outcomes for patients with ovarian cancer. This evidence concerns the gene RAD51 and ovarian carcinoma.